The Birmingham Rheumatoid Arthritis Model (BRAM) has been developed over a number of years to inform several appraisals of biologic drugs by the Technology Appraisals Committee of the UK National Institute for Health and Clinical Excellence. This article describes the processes used in the construction of the different versions of the BRAM.
|Publication status||Published - 1 Sept 2011|
- Cost-effectiveness analysis
- Rheumatoid arthritis
- Biologic therapies